viewValiRx PLC

ValiRX raises funds to meet immediate working capital needs and develop drugs

ValiRX expects to pay European High Growth Opportunities Securitisation Fund up to £150,000 to terminate a subscription agreement.

ValiRX will also receive £550K from a tax credit and the sale of an unlisted security

ValiRx Plc (LON:VAL) has raised £300,000 through a share placing to address its immediate working capital needs and to develop key drugs.

The biotechnology company issued 150mln new ordinary shares at a price of 0.2p per share.

READ: ValiRx monitors working capital position amid talks to end subscription agreement with investor

The net proceeds of the placing will be used for working capital and to fund the Phase I/II clinical trial of prostate cancer treatment, VAL201, and to develop ValiRx's pre-clinical treatments, including VAL301 for endometriosis and VAL101 for killing off cancer cells.

ValiRX also expects to shortly receive £150,000 in proceeds from the sale of an unlisted security along with a research and development tax credit of £400,000 from the HMRC in July.

The company has been monitoring its working capital position as talks to terminate a subscription agreement with European High Growth Opportunities Securitisation Fund continue.

In late April, European High Growth agreed to subscribe for a total of 213mln shares in ValiRX at a price of 0.6p each, raising gross proceeds of £1.28mln.

The money was to be drawn down in three equal tranches of £426,000, which would have helped fund the Phase II trial of ValiRx's prostate cancer drug, VAL201, through to completion.

However, last month ValiRX said it was in advanced discussions to terminate the agreement following a delay to the issue of Tranche 2 shares.

On Thursday, ValiRX said it had still not reached a definitive agreement with European High Growth but expects to pay the investor up to £150,000 to end the deal.

Quick facts: ValiRx PLC

Price: 53.5 GBX

Market: AIM
Market Cap: £31.35 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...


Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

2 min read